View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsPCAS 過去の業績過去 基準チェック /26PCASの収益は年間平均-40.1%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.9% 0.7%割合で 増加しています。 PCASの自己資本利益率は122.1%であり、純利益率は3.8%です。主要情報-40.14%収益成長率-40.15%EPS成長率Life Sciences 業界の成長26.83%収益成長率0.67%株主資本利益率122.06%ネット・マージン3.81%前回の決算情報30 Jun 2023最近の業績更新分析記事 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).お知らせ • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).すべての更新を表示Recent updates分析記事 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.6m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€53m free cash flow). Negative equity (-€18m). Earnings have declined by 63% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€88.6m market cap, or US$96.4m).お知らせ • Jun 02DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA).DIC Corporation (TSE:4631) agreed to acquire PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) for an enterprise value of €88.2 million on May 25, 2023. The sale is not subject to any condition precedents. Therefore, the execution of the related agreements by PCAS and DIC Corporation as well as the closing of the transaction will be completed within the coming days. DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) on June 1, 2023. On completion, PCAS Canada Inc was renamed “Innovation DIC Chimitroniques Inc.” (English company name: “Innovation DIC Chemitronics Inc.”).お知らせ • May 09PCAS in Talks to Sell Canada Unit to DICPCAS SA (ENXTPA:PCA) announced it has entered into exclusive talks to sell its Canadian subsidiary to DIC Corporation (TSE:4631). The proposed deal gives PCAS Canada Inc. an enterprise value of EUR 88.2 million (USD 97.1 million). A potential transaction hinges on an obligatory information-consultation process of the competent workers’ councils, after authorisation of PCAS’ supervisory board and its majority shareholder, Seqens, a press release said.Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).お知らせ • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Director Jacqueline Lecourtier was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Chairman of the Board Pierre Luzeau was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.分析記事 • Dec 19Is PCAS (EPA:PCA) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.分析記事 • May 24Is PCAS (EPA:PCA) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...分析記事 • Mar 02Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).お知らせ • Feb 26PCAS SA, Annual General Meeting, May 12, 2021PCAS SA, Annual General Meeting, May 12, 2021, at 10:00 Central European Standard Time.Is New 90 Day High Low • Feb 06New 90-day high: €11.50The company is up 16% from its price of €9.95 on 05 November 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.お知らせ • Jan 29PCAS SA to Report Fiscal Year 2020 Results on Feb 25, 2021PCAS SA announced that they will report fiscal year 2020 results on Feb 25, 2021Is New 90 Day High Low • Jan 20New 90-day high: €10.70The company is up 3.0% from its price of €10.40 on 22 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 3.0% over the same period.分析記事 • Nov 25PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...Is New 90 Day High Low • Nov 11New 90-day low: €9.25The company is down 16% from its price of €11.00 on 12 August 2020. The French market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.収支内訳PCAS の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史ENXTPA:PCA 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 232309149031 Mar 23228-20149031 Dec 22226-49149030 Sep 22208-58146030 Jun 22191-67143031 Mar 22189-54140031 Dec 21187-40137030 Sep 21191-27135030 Jun 21195-14133031 Mar 21195-15132031 Dec 20194-15132030 Sep 20199-13131030 Jun 20204-11130031 Mar 20202-12127031 Dec 19201-14123030 Sep 19205-9181030 Jun 19209-6120031 Mar 19208-3119031 Dec 182070119030 Sep 18208-159030 Jun 182080117031 Mar 182133115031 Dec 172186114030 Sep 172106110030 Jun 172026107031 Mar 171976105031 Dec 161927103030 Sep 161917101030 Jun 16189898031 Mar 16184895031 Dec 15179992030 Sep 15175789030 Jun 15172587031 Mar 15169486031 Dec 14166384030 Sep 14164284030 Jun 14161283031 Mar 14163384031 Dec 13165384030 Jun 13171684031 Mar 13171684031 Dec 121716850質の高い収益: PCA 非現金収入 のレベルが高いです。利益率の向上: PCA過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PCA過去 5 年間で収益を上げており、収益は年間-40.1%増加しています。成長の加速: PCAは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: PCA昨年収益を上げたため、昨年の収益成長をLife Sciences業界 ( 5.4% ) と比較することは困難です。株主資本利益率高いROE: PCAの 自己資本利益率 ( 122.06% ) は 抜群 ですが、負債レベルが高いためこの指標は歪んでいます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/12/11 11:23終値2023/12/08 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PCAS SA これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Harold De DeckerODDO BHF Corporate & MarketsGeoffroy MichaletPortzamparc BNP ParibasPierre VauriceTPICAP Midcap
分析記事 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...
Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).
お知らせ • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023
Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.
Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).
分析記事 • Sep 14Statutory Earnings May Not Be The Best Way To Understand PCAS' (EPA:PCA) True PositionPCAS SA's ( EPA:PCA ) stock rose after it released a robust earnings report. Despite the strong profit numbers, we...
New Risk • Aug 18New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €88.6m (US$96.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€53m free cash flow). Negative equity (-€18m). Earnings have declined by 63% per year over the past 5 years. Minor Risk Market cap is less than US$100m (€88.6m market cap, or US$96.4m).
お知らせ • Jun 02DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA).DIC Corporation (TSE:4631) agreed to acquire PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) for an enterprise value of €88.2 million on May 25, 2023. The sale is not subject to any condition precedents. Therefore, the execution of the related agreements by PCAS and DIC Corporation as well as the closing of the transaction will be completed within the coming days. DIC Corporation (TSE:4631) completed the acquisition of PCAS Canada Inc. from PCAS SA (ENXTPA:PCA) on June 1, 2023. On completion, PCAS Canada Inc was renamed “Innovation DIC Chimitroniques Inc.” (English company name: “Innovation DIC Chemitronics Inc.”).
お知らせ • May 09PCAS in Talks to Sell Canada Unit to DICPCAS SA (ENXTPA:PCA) announced it has entered into exclusive talks to sell its Canadian subsidiary to DIC Corporation (TSE:4631). The proposed deal gives PCAS Canada Inc. an enterprise value of EUR 88.2 million (USD 97.1 million). A potential transaction hinges on an obligatory information-consultation process of the competent workers’ councils, after authorisation of PCAS’ supervisory board and its majority shareholder, Seqens, a press release said.
Reported Earnings • Apr 02Full year 2022 earnings releasedFull year 2022 results: Revenue: €226.4m (up 21% from FY 2021). Net loss: €48.8m (loss widened 21% from FY 2021).
お知らせ • Feb 07PCAS SA to Report Fiscal Year 2022 Results on Mar 30, 2023PCAS SA announced that they will report fiscal year 2022 results on Mar 30, 2023
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. 1 independent director (3 non-independent directors). Independent Director Jacqueline Lecourtier was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Chairman of the Board Pierre Luzeau was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 28Full year 2021 earnings: Revenues miss analyst expectationsFull year 2021 results: Revenue: €187.0m (down 3.7% from FY 2020). Net loss: €40.5m (loss widened 171% from FY 2020). Revenue missed analyst estimates by 1.8%.
分析記事 • Dec 19Is PCAS (EPA:PCA) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Sep 12First half 2021 earnings released: €0.38 loss per share (vs €0.42 loss in 1H 2020)The company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €106.3m (up 1.1% from 1H 2020). Net loss: €5.21m (loss narrowed 11% from 1H 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 57 percentage points per year, which is a significant difference in performance.
分析記事 • May 24Is PCAS (EPA:PCA) Weighed On By Its Debt Load?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
分析記事 • Mar 02Did You Miss PCAS' (EPA:PCA) 48% Share Price Gain?These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But the truth is...
Reported Earnings • Mar 02Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €194.1m (down 3.4% from FY 2019). Net loss: €14.9m (loss widened 8.8% from FY 2019).
お知らせ • Feb 26PCAS SA, Annual General Meeting, May 12, 2021PCAS SA, Annual General Meeting, May 12, 2021, at 10:00 Central European Standard Time.
Is New 90 Day High Low • Feb 06New 90-day high: €11.50The company is up 16% from its price of €9.95 on 05 November 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.
お知らせ • Jan 29PCAS SA to Report Fiscal Year 2020 Results on Feb 25, 2021PCAS SA announced that they will report fiscal year 2020 results on Feb 25, 2021
Is New 90 Day High Low • Jan 20New 90-day high: €10.70The company is up 3.0% from its price of €10.40 on 22 October 2020. The French market is up 14% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 3.0% over the same period.
分析記事 • Nov 25PCAS'(EPA:PCA) Share Price Is Down 48% Over The Past Three Years.In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
Is New 90 Day High Low • Nov 11New 90-day low: €9.25The company is down 16% from its price of €11.00 on 12 August 2020. The French market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 11% over the same period.